Drugs from the GLP-1RA group targeting the GLP-1R, reduce damage caused by hypoperfusion through the interaction of pleiotropic pathways and signaling cascades, including those involved in mutual regulation of the gut and brain, thereby opening up new prospects for the treatment of neurocognitive disorders
Endogenous GLP-1 and GLP-1RAs differ significantly in their pharmacokinetics, mechanisms of action, and physiological effects
The evidence base for probiotics in this context does not meet the standards required for inclusion in clinical guidelines, and NICE emphasises multicomponent lifestyle interventions alongside licensed pharmacological options when appropriate
But some GLP-1 medications are FDA-approved to reduce the risk of major cardiovascular events, such as heart attack and stroke, in certain people with Type 2 diabetes or obesity
In a retrospective study GLP-1 agonists have been shown to be associated with lower rates of hepatic decompensations compared to other glycemic agents, although more prospective data is needed
